{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:02:41Z","timestamp":1787022161592,"version":"build-2736575974"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chongqing Science and Health Joint Medical Research Program","award":["2022MSXM084"],"award-info":[{"award-number":["2022MSXM084"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Assessing the potential for oseltamivir-induced liver damage is essential to ensure its safe administration. The aim of this study was to examine the association between hepatotoxicity and oseltamivir use and to describe the features of oseltamivir-induced hepatotoxicity. Data were obtained from the Adverse Event Reporting System of the US Food and Drug Administration (FAERS). Disproportionality and proportionality analyses were performed to evaluate the safety profile of oseltamivir-related hepatotoxicity and the occurrence of hepatotoxicity-related adverse events across sex and age groups. The FAERS recorded 20,340,254 adverse event reports between 2004 and 2023, of which 16,960,996 reports were included in the analysis. We identified 14 types of oseltamivir-related adverse events that were hepatotoxic and showed positive signals. The most frequently reported adverse event was abnormal hepatic function (n =\u2009 54), and the most severe adverse event was fulminant hepatitis. Compared with that for male individuals, the reporting odds ratio (ROR) was 0.5 for female individuals; and for male individuals, the ROR, compared with that for female individuals, was 4.19. The median time to hepatotoxic adverse events, excluding mixed liver injury, was &lt;\u2009 5 days. Oseltamivir can cause liver toxicity, which is influenced by sex and age. Liver function tests and monitoring for signs of liver disease are crucial when using oseltamivir.<\/jats:p>","DOI":"10.1371\/journal.pone.0314970","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T13:43:41Z","timestamp":1740491021000},"page":"e0314970","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Oseltamivir-induced hepatotoxicity: A retrospective analysis of the FDA adverse event reporting system"],"prefix":"10.1371","volume":"20","author":[{"given":"Lurong","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiumeng","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6342-8539","authenticated-orcid":true,"given":"Limei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"pone.0314970.ref001","doi-asserted-by":"crossref","first-page":"682732","DOI":"10.3389\/fphar.2021.682732","article-title":"Efficacy and safety of Chinese patent medicine combined with oseltamivir in treatment of children with influenza: a meta-analysis","volume":"12","author":"N-F Duan","year":"2021","journal-title":"Front Pharmacol"},{"key":"pone.0314970.ref002","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijid.2022.12.043","article-title":"Comparative effectiveness of oseltamivir versus peramivir for hospitalized children (aged 0-5 years) with influenza infection","volume":"128","author":"M Xu","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"2","key":"pone.0314970.ref003","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/cpt.3107","article-title":"An observational study on the pharmacokinetics of oseltamivir in lactating influenza patients","volume":"115","author":"E Fodor","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"pone.0314970.ref004","first-page":"1199","article-title":"Use of oseltamivir in children","volume":"55","author":"B Jamieson","year":"2009","journal-title":"Can Fam Physician"},{"issue":"2","key":"pone.0314970.ref005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5152\/TurkPediatriArs.2016.2359","article-title":"Influenza and the use of oseltamivir in children","volume":"51","author":"E \u00c7ift\u00e7i","year":"2016","journal-title":"Turk Pediatri Ars"},{"issue":"8","key":"pone.0314970.ref006","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3109\/00365548.2012.669844","article-title":"Survey of Japanese infants younger than 3 months who were treated with oseltamivir for influenza: safety of oseltamivir treatment","volume":"44","author":"I Morioka","year":"2012","journal-title":"Scand J Infect Dis"},{"issue":"7","key":"pone.0314970.ref007","first-page":"654","article-title":"Oseltamivir-associated supraventricular tachycardia in an infant","volume":"25","author":"EC Bodo","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"9","key":"pone.0314970.ref008","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/23744235.2016.1189592","article-title":"The mechanisms of delayed onset type adverse reactions to oseltamivir","volume":"48","author":"R Hama","year":"2016","journal-title":"Infect Dis (Lond)"},{"issue":"38","key":"pone.0314970.ref009","doi-asserted-by":"crossref","first-page":"e12497","DOI":"10.1097\/MD.0000000000012497","article-title":"Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir: a case report","volume":"97","author":"S Fang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"pone.0314970.ref010","first-page":"205","article-title":"First case of acute cholestatic hepatitis attributed to oseltamivir in a young girl with ah1n1 influenza","volume":"33","author":"A Mastroianni","year":"2021","journal-title":"Ann Ig"},{"issue":"3\u20135","key":"pone.0314970.ref011","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/13596535211041494","article-title":"Oseltamivir and acute hepatitis, reality association or coincidence?","volume":"26","author":"A Mastroianni","year":"2021","journal-title":"Antivir Ther"},{"issue":"5","key":"pone.0314970.ref012","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.jaip.2023.01.027","article-title":"Differences in hypersensitivity reactions to iodinated contrast media: analysis of the US food and drug administration adverse event reporting system database","volume":"11","author":"X Lin","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"pone.0314970.ref013","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-Induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS)","volume":"1","author":"K Anand","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"6","key":"pone.0314970.ref014","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"J-L Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"pone.0314970.ref015","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS)","volume":"12","author":"S Cirmi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"10","key":"pone.0314970.ref016","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/23744235.2023.2234476","article-title":"Management of influenza - updated Swedish guidelines for antiviral treatment","volume":"55","author":"J Westin","year":"2023","journal-title":"Infect Dis (Lond)"},{"issue":"3","key":"pone.0314970.ref017","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1521\/bumc.65.3.427.19844","article-title":"The human genome and the representational world: the role of early mother-infant interaction in creating an interpersonal interpretive mechanism","volume":"65","author":"P Fonagy","year":"2001","journal-title":"Bull Menninger Clin"},{"issue":"5","key":"pone.0314970.ref018","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/FJC.0000000000001002","article-title":"Adverse effects of oseltamivir phosphate therapy on the liver of LDLR-\/- mice without any benefit on atherosclerosis and thrombosis","volume":"77","author":"O Bocquet","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"pone.0314970.ref019","first-page":"71","article-title":"Safety of oseltamivir in infants less than one year old: prospective surveillance during the 2004\u20132005 influenza season in Japan","volume":"8","author":"T Tahara","year":"2013","journal-title":"J Pediatr Infect Dis"},{"issue":"6","key":"pone.0314970.ref020","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bcpt.12625","article-title":"Association of oseltamivir activation with gender and carboxylesterase 1 genetic polymorphisms","volume":"119","author":"J Shi","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"3","key":"pone.0314970.ref021","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1208\/s12249-020-1638-y","article-title":"Simulation of the pharmacokinetics of oseltamivir and its active metabolite in normal populations and patients with hepatic cirrhosis using physiologically based pharmacokinetic modeling","volume":"21","author":"Y Chen","year":"2020","journal-title":"AAPS Pharm Sci Tech"},{"issue":"1","key":"pone.0314970.ref022","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/11536950-000000000-00000","article-title":"Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant","volume":"13","author":"SM Abdel-Rahman","year":"2011","journal-title":"Paediatr Drugs"},{"issue":"12","key":"pone.0314970.ref023","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"RK Verbeeck","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"pone.0314970.ref024","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1592\/phco.30.1.35","article-title":"Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin","volume":"30","author":"MR Goldberg","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"5","key":"pone.0314970.ref025","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2125.2005.02340.x","article-title":"Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate","volume":"59","author":"P Snell","year":"2005","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"pone.0314970.ref026","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/AAC.00588-08","article-title":"Pharmacokinetics of high-dose oseltamivir in healthy volunteers","volume":"53","author":"Y Wattanagoon","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0314970.ref027","doi-asserted-by":"crossref","first-page":"e2023063773","DOI":"10.1542\/peds.2023-063773","article-title":"Recommendations for prevention and control of influenza in children, 2023-2024","volume":"152","author":"Committee on Infectious Diseases","year":"2023","journal-title":"Pediatrics"},{"key":"pone.0314970.ref028","unstructured":"US FDA drug database. 2023 Oct 24 [cited 18 Oct 2024] Available from: https:\/\/www.drugfuture.com\/fda\/drugview\/021036"},{"key":"pone.0314970.ref029","first-page":"NBK548527","author":"Zanamivir","year":"2020"},{"key":"pone.0314970.ref030","author":"Peramivir","year":"2020 Jun 22"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0314970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T13:43:54Z","timestamp":1740491034000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0314970"}},"subtitle":[],"editor":[{"given":"Shih-Chao","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0314970","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]}}}